{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:45:28Z","timestamp":1794638728542,"version":"4.9.1"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cytogfr.2026.06.001","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T15:49:35Z","timestamp":1781884175000},"page":"80-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Temporal dynamics of type I interferon signaling in checkpoint inhibitor response and resistance"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9028-0946","authenticated-orcid":false,"given":"Andrew","family":"Thake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cytogfr.2026.06.001_bib1","doi-asserted-by":"crossref","first-page":"71249","DOI":"10.18632\/oncotarget.19531","article-title":"Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy","volume":"8","author":"Medrano","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cytogfr.2026.06.001_bib2","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/s41422-019-0224-x","article-title":"Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade","volume":"29","author":"Jacquelot","year":"2019","journal-title":"Cell. Res."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev-pathol-031920-093932","article-title":"Opposing Roles of Type I Interferons in Cancer Immunity","volume":"16","author":"Boukhaled","year":"2021","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib4","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","article-title":"Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade","volume":"178","author":"Benci","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2026.06.001_bib5","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2026.06.001_bib6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12943-025-02495-4","article-title":"Context-dependent impact of type I interferon signaling in cancer","volume":"24","author":"Ruiz-Iglesias","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cytogfr.2026.06.001_bib7","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41590-022-01290-3","article-title":"Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B","volume":"23","author":"Musella","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/imr.13272","article-title":"Type I interferon and cancer","volume":"321","author":"Holicek","year":"2024","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib9","article-title":"The curious case of type I interferon signaling in cancer","volume":"1879","author":"Chhipa","year":"2024","journal-title":"Biochim. Biophys. Acta BBA - Rev. Cancer"},{"key":"10.1016\/j.cytogfr.2026.06.001_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.782852","article-title":"Antiviral Responses in Cancer: Boosting Antitumor Immunity Through Activation of Interferon Pathway in the Tumor Microenvironment","volume":"12","author":"Vitiello","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-020-00916-z","article-title":"cGAS-STING, an important pathway in cancer immunotherapy","volume":"13","author":"Jiang","year":"2020","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib12","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s13046-025-03555-9","article-title":"Bridging innate and adaptive tumor immunity: cGAS\u2013STING pathway activation to potentiate immune checkpoint blockade","volume":"44","author":"Li","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib13","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/1078-0432.CCR-15-1362","article-title":"Molecular pathways: targeting the stimulator of interferon genes (STING) in the immunotherapy of cancer","volume":"21","author":"Corrales","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-immunol-032414-112043","article-title":"Innate Immune Recognition of Cancer","volume":"33","author":"Woo","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib15","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/nature05732","article-title":"TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity","volume":"446","author":"Gack","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2026.06.001_bib16","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41577-020-0288-3","article-title":"RIG-I-like receptors: their regulation and roles in RNA sensing","volume":"20","author":"Rehwinkel","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib17","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cytogfr.2007.06.002","article-title":"Convergence of the NF-\u03baB and IRF pathways in the regulation of the innate antiviral response","volume":"18","author":"Hiscott","year":"2007","journal-title":"Cytokine Growth Factor. Rev."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib18","doi-asserted-by":"crossref","first-page":"15325","DOI":"10.1074\/jbc.R700002200","article-title":"Triggering the Innate Antiviral Response through IRF-3 Activation","volume":"282","author":"Hiscott","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41698-019-0093-2","article-title":"Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC","volume":"3","author":"Brockwell","year":"2019","journal-title":"Npj Precis. Oncol."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib20","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.bbadis.2010.02.006","article-title":"ISG15 and immune diseases","volume":"1802","author":"Jeon","year":"2010","journal-title":"Biochim. Biophys. Acta BBA - Mol. Basis Dis."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrc3258","article-title":"Cancer immunotherapy via dendritic cells","volume":"12","author":"Palucka","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cytogfr.2026.06.001_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s43018-022-00490-y","article-title":"Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction","author":"Qiu","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.cytogfr.2026.06.001_bib23","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature09907","article-title":"A diverse range of gene products are effectors of the type I interferon antiviral response","volume":"472","author":"Schoggins","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2026.06.001_bib24","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.coviro.2011.10.008","article-title":"Interferon-stimulated genes and their antiviral effector functions","volume":"1","author":"Schoggins","year":"2011","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib25","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.it.2016.09.006","article-title":"Dendritic Cells and Cancer Immunity","volume":"37","author":"Gardner","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1547466","article-title":"The role of type I interferon signaling in myeloid anti-tumor immunity","volume":"16","author":"Meyer","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib27","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1084\/jem.20101159","article-title":"Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8\u03b1+ dendritic cells","volume":"208","author":"Fuertes","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib28","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib29","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","article-title":"Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy","volume":"50","author":"Chow","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2026.06.001_bib30","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib31","doi-asserted-by":"crossref","first-page":"5266","DOI":"10.3390\/ijms26115266","article-title":"Targeting Lineage-Specific Functions of NR4A1 for Cancer Immunotherapy","volume":"26","author":"Kleberg","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13073-020-00722-9","article-title":"Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer","volume":"12","author":"Kim","year":"2020","journal-title":"Genome Med."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111647","article-title":"Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8+ T cell exhaustion and curtails anti-PD-1 efficacy","volume":"41","author":"Chen","year":"2022","journal-title":"Cell. Rep."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib34","doi-asserted-by":"crossref","first-page":"7243","DOI":"10.1038\/s41598-021-86644-x","article-title":"cGAS\u2013STING cytosolic DNA sensing pathway is suppressed by JAK2-STAT3 in tumor cells","volume":"11","author":"Suter","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib35","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1038\/s41467-022-32567-8","article-title":"Temporally restricted activation of IFN\u03b2 signaling underlies response to immune checkpoint therapy in mice","volume":"13","author":"Zemek","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib36","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00018-022-04219-z","article-title":"Type I interferon-mediated tumor immunity and its role in immunotherapy","volume":"79","author":"Yu","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib37","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1158\/1078-0432.CCR-20-2564","article-title":"Type I IFN Activating Type I Dendritic Cells for Antitumor Immunity","volume":"27","author":"Liang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib38","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1073\/pnas.1621363114","article-title":"cGAS is essential for the antitumor effect of immune checkpoint blockade","volume":"114","author":"Wang","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib39","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.85263","article-title":"Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against tumors with heterogeneous neoantigen expression","volume":"12","author":"Nguyen","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.cytogfr.2026.06.001_bib40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The Three Es of Cancer Immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib41","doi-asserted-by":"crossref","DOI":"10.1186\/s12645-022-00116-z","article-title":"Delivery of CXCL9\/10\/11 plasmid DNAs promotes the tumor-infiltration of T cells and synergizes with PD1 antibody for treating lung cancer","volume":"13","author":"Ma","year":"2022","journal-title":"Cancer Nanotechnol."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1452212","article-title":"PD-1 and CTLA-4 serve as major gatekeepers for effector and cytotoxic T-cell potentiation by limiting a CXCL9\/10-CXCR3-IFN\u03b3 positive feedback loop","volume":"15","author":"Abdala-Saleh","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib43","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00262-020-02497-9","article-title":"Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients","volume":"69","author":"Kasanen","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib44","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1158\/1538-7445.AM2024-2660","article-title":"Abstract 2660: CXCL9\/10 is critical for immunotherapeutic efficacy by recruiting and activating T lymphocytes in tumor microenvironment","volume":"84","author":"Cheng","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib45","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20241148","article-title":"Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection","volume":"222","author":"Broomfield","year":"2025","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib46","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s44319-024-00333-0","article-title":"Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors","volume":"26","author":"Shi","year":"2024","journal-title":"EMBO Rep."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib47","doi-asserted-by":"crossref","first-page":"352","DOI":"10.20517\/jtgg.2025.90","article-title":"Persistent IFN-\u03b3 signaling in acquired resistance to PD-(L)1 blockade in NSCLC","volume":"9","author":"Karri","year":"2025","journal-title":"J. Transl. Genet. Genom."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib48","article-title":"Targeting Interferon-Driven","author":"Qiu","year":"2024","journal-title":"Inflamm. Mem. Prev. Epigenetic Evol. Cancer Immunother. Resist."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib49","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.molimm.2018.01.014","article-title":"Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer","volume":"110","author":"Chrisikos","year":"2018","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib50","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.it.2015.09.007","article-title":"Interferons and the Immunogenic Effects of Cancer Therapy","volume":"36","author":"Minn","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01443","article-title":"Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy","volume":"9","author":"Fazio","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib52","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1172\/JCI70408","article-title":"Pegylated IFN-\u03b1 regulates hepatic gene expression through transient Jak\/STAT activation","volume":"124","author":"Dill","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib53","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00262-024-03761-y","article-title":"Tumor-intrinsic IFN\u03b1 and CXCL10 are critical for immunotherapeutic efficacy by recruiting and activating T lymphocytes in tumor microenvironment","volume":"73","author":"Cheng","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-35348-5","article-title":"Expansion of interferon inducible gene pool via USP18 inhibition promotes cancer cell pyroptosis","volume":"14","author":"Arimoto","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib55","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41419-026-08607-2","article-title":"The cGAS-STING pathway in cancer: friend or foe","volume":"17","author":"Li","year":"2026","journal-title":"Cell. Death Dis."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib56","article-title":"The Resistance Mechanisms of Lung Cancer Immunotherapy","volume":"10","author":"Wang","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib57","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70274","article-title":"Improvement of the Anticancer Efficacy of PD-1\/PD-L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies","volume":"6","author":"Gao","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.cytogfr.2026.06.001_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2025.1622115","article-title":"The power and the promise of epigenetic drugs in oncology","volume":"16","author":"Scandolara","year":"2026","journal-title":"Front. Genet."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib59","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb0152","article-title":"Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma","volume":"12","author":"Kalbasi","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib60","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41423-021-00735-3","article-title":"IFN\u03b3 signaling integrity in colorectal cancer immunity and immunotherapy","volume":"19","author":"Du","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib61","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1200\/JCO.2019.37.15_suppl.2584","article-title":"Overcoming genetically based resistance mechanisms to PD-1 blockade","volume":"37","author":"Torrejon","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib62","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1038\/s41467-020-15726-7","article-title":"Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition","volume":"11","author":"Lee","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib63","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.3390\/ijms26189008","article-title":"STINGing Cancer: Development, Clinical Application, and Targeted Delivery of STING Agonists","volume":"26","author":"Nerdinger","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib64","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1038\/s41467-019-13094-5","article-title":"An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases","volume":"10","author":"Liu","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib65","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s43018-023-00584-1","article-title":"Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer","volume":"4","author":"Perelli","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.cytogfr.2026.06.001_bib66","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13039-019-0429-1","article-title":"The emerging links between chromosomal instability (CIN), metastasis, inflammation and tumour immunity","volume":"12","author":"Tijhuis","year":"2019","journal-title":"Mol. Cytogenet."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib67","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/s41586-023-06464-z","article-title":"Non-cell-autonomous cancer progression from chromosomal instability","volume":"620","author":"Li","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2026.06.001_bib68","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3390\/cells8101228","article-title":"The cGAS Paradox: Contrasting Roles for cGAS-STING Pathway in Chromosomal Instability","volume":"8","author":"Hong","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.cytogfr.2026.06.001_bib69","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1158\/1078-0432.CCR-23-0215","article-title":"Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma","volume":"29","author":"Horowitch","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib70","doi-asserted-by":"crossref","first-page":"144","DOI":"10.33696\/cancerimmunol.7.113","article-title":"Next-Generation Immune Checkpoint Inhibitors in Cancer: Mechanisms, Current Clinical Advances, and Future Directions","volume":"7","author":"Hussain","year":"2025","journal-title":"J. Cancer Immunol."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib71","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41422-023-00876-2","article-title":"Chromosomal instability drives immunosuppression and metastatic dissemination","volume":"34","author":"Vitale","year":"2023","journal-title":"Cell. Res."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib72","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12672-025-04361-7","article-title":"Immune checkpoint blockade in cancer: current insights and future horizons","volume":"17","author":"Saman","year":"2026","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.cytogfr.2026.06.001_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1685931","article-title":"The cGAS-STING signaling pathway: emerging targets and challenges in breast cancer immunotherapy","volume":"16","author":"Sun","year":"2026","journal-title":"Front. Immunol."}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610126000444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610126000444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:12:55Z","timestamp":1783635175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610126000444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":73,"alternative-id":["S1359610126000444"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2026.06.001","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Temporal dynamics of type I interferon signaling in checkpoint inhibitor response and resistance","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2026.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}